Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.
about
SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinomaEndothelial Transdifferentiation of Tumor Cells Triggered by the Twist1-Jagged1-KLF4 Axis: Relationship between Cancer Stemness and AngiogenesisOverview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial FluidPersonalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistanceAurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosisSerine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.EGFR-TKI resistance in NSCLC patients: mechanisms and strategiesGefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationPredictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivoBioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancerUbiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells.Slug contributes to cancer progression by direct regulation of ERα signaling pathwayTriclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cellsNext-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibAberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival.Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression.Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.Erlotinib resistance in lung cancer: current progress and future perspectives.Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorSilibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivoLocal microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatmeSide population cells from long-term passage non-small cell lung cancer cells display loss of cancer stem cell-like properties and chemoradioresistance.Long range personalized cancer treatment strategies incorporating evolutionary dynamics.DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive propertiesHighly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse.Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma.Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance.Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/ STAT3 and TGF-β/SMAD3 signaling pathwaySurfactant-based drug delivery systems for treating drug-resistant lung cancer.miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway.Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells.Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibitionMoscatilin inhibits epithelial-to-mesenchymal transition and sensitizes anoikis in human lung cancer H460 cells.Resistance to Therapy.Expression of HMGA2 in bladder cancer and its association with epithelial-to-mesenchymal transition.
P2860
Q23920671-549A604E-BE2F-4411-9B3A-DBF4F40465DFQ26773015-39F0DAC0-320E-4088-BC88-A98CFDF76695Q26799981-A7E12996-AF6C-44FD-972C-7B5EBF7AFC1EQ26866517-A44266F0-0F16-43A1-ADE2-A55AEF783024Q27853047-988205BD-42B0-4756-A62E-BFF69514776AQ28115436-84A77126-91B5-4BCD-B9FD-DECE23FCA46FQ28394310-EB4FE871-353D-4BF8-860C-4EDFFEDB38FBQ28534577-798D94C5-01BA-4121-A5FE-6AA8EA4406AAQ33567383-5F504699-203F-4539-9C94-196285CD25EAQ34141440-A3C291D0-115B-4FFD-8BDF-6F2537A78FDFQ34295621-BFD49C9A-BCE9-4095-9ADF-8BBDB3948DA9Q34381561-93E60152-0040-4656-A7F4-E9A2EA901118Q35168129-34C52B71-C31E-441D-8F54-5AA387D9C448Q35347566-36DC8C9D-11A8-4DE1-8FEA-31F93350805FQ35807946-E6A3B1CF-3AF1-4EEC-B929-D0C34D64890DQ36085659-30975649-4277-4E43-BA65-A35BBBF7914BQ36095123-B0BDBD9C-9B71-45C9-9623-1E6CD8D10B65Q36287390-5E520141-9305-4D63-A16D-78B824AAECC3Q36557486-0CD8C9FB-43C4-4DCD-BCCD-28965D2299D1Q36605522-6E790824-688E-48BD-A048-864C672D247EQ37011144-6ED01060-3663-40F8-AB18-4EB3F982CFB8Q37107787-9C2E0B4C-68DB-44C4-8A9F-082F5C852330Q37205228-4E15384B-51BB-4F8A-A947-D3E6AC9AF7E5Q37287419-32902ACA-1824-40E3-8F69-E7E8417D3971Q37358959-C63A7BB4-F8CB-42B6-82E3-9B778430CCBCQ37426768-2660F00C-14F8-40C2-A9F9-B6B3D4D1F29BQ37575786-E86AA58A-D7C3-47BA-8A18-D85688145308Q37634419-15362146-47C5-4E81-8996-8631F7317C93Q37642507-B09104F6-C6D5-4F1E-8439-5A4F59FCF75DQ37666114-5DC8B365-C659-4498-8298-94B22DF778BBQ37666880-858A7935-4992-456F-895C-C7413F39E47AQ37701508-2DA468FA-BF96-4A0C-A043-42BB723133FDQ38228362-7728FAD9-7531-4129-8520-85E13D95672CQ38727344-C0BC0933-B6E8-4FA7-8BFF-81EF9FCE5C55Q38771817-C1BB0559-CD5C-45D2-9B93-1F00B66EAAB8Q38791381-41D954BF-7BEA-4DBF-B39D-2B8FD5FFAAF3Q38823644-EFE5D135-250E-41C0-877C-314A7AB2A381Q38834297-F58BF516-4FA6-43D2-8AB3-063C2F3D5E7DQ38930367-A95B151B-C259-49E3-BC8A-BC4708027DBFQ39020752-24C904A1-0806-4FDC-A27A-F794ED40D25C
P2860
Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.
@en
type
label
Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.
@en
prefLabel
Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.
@en
P2093
P2860
P1476
Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer.
@en
P2093
Akiko Murakami
Fariz Nurwidya
Fumiyuki Takahashi
Kazuhisa Takahashi
P2860
P304
P356
10.4143/CRT.2012.44.3.151
P577
2012-09-30T00:00:00Z